Literature DB >> 8958912

Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo.

M K Gately1, D M Carvajal, S E Connaughton, S Gillessen, R R Warrier, K D Kolinsky, V L Wilkinson, C M Dwyer, G F Higgins, F J Podlaski, D A Faherty, P C Familletti, A S Stern, D H Presky.   

Abstract

Mo(p40)2 is a potent IL-12 antagonist that interacts strongly with the beta 1 subunit of the IL-12R to block binding of moIL-12 to the high-affinity mouse IL-12R. Mo(p40)2, alone or in synergy with the 2B5 mAb specific for the moIL-12 heterodimer, blocked IL-12-induced responses in vitro, Mo(p40)2 was thus used alone or with 2B5 mAb to examine the role of IL-12 in vivo, Mo(p40)2 caused a dose-dependent inhibition of both the rise in serum IFN-gamma levels in mice injected with endotoxin and the Th1-like response to immunization with KLH. Treatment with mo(p40)2 plus 2B5 anti-moIL-12 mAb also suppressed DTH responses to methylated bovine serum albumin but not specific allogeneic CTL responses in vivo. In each of these models, responses seen in mice treated with mo(p40)2 +/- 2B5 anti-moIL-12 mAb were similar to those observed in IL-12 knockout mice. Thus, mo(p40)2 can act as a potent IL-12 antagonist in vivo, as well as in vitro, and is currently being used to investigate the role of IL-12 in the pathogenesis of some Th1-associated autoimmune disorders in mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958912     DOI: 10.1111/j.1749-6632.1996.tb52650.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  38 in total

1.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice.

Authors:  Yongxia Wu; David Bastian; Steven Schutt; Hung Nguyen; Jianing Fu; Jessica Heinrichs; Changqing Xia; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-04       Impact factor: 5.742

Review 3.  IL-12 family cytokines: immunological playmakers.

Authors:  Dario A A Vignali; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2012-07-19       Impact factor: 25.606

4.  Deficiency in the serum-derived hyaluronan-associated protein-hyaluronan complex enhances airway hyperresponsiveness in a murine model of asthma.

Authors:  Long Zhu; Lisheng Zhuo; Koji Kimata; Etsuro Yamaguchi; Hideto Watanabe; Mark A Aronica; Vincent C Hascall; Kenji Baba
Journal:  Int Arch Allergy Immunol       Date:  2010-05-18       Impact factor: 2.749

Review 5.  Modulation of the host's immune response by schistosome larvae.

Authors:  S J Jenkins; J P Hewitson; G R Jenkins; A P Mountford
Journal:  Parasite Immunol       Date:  2005 Oct-Nov       Impact factor: 2.280

6.  The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller
Journal:  J Gastroenterol Hepatol       Date:  2019-02-25       Impact factor: 4.029

7.  Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.

Authors:  Yanira Osorio; Homayon Ghiasi
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 8.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

Review 9.  Interleukin 12 a key immunoregulatory cytokine in infection applications.

Authors:  Therwa Hamza; John B Barnett; Bingyun Li
Journal:  Int J Mol Sci       Date:  2010-02-26       Impact factor: 5.923

10.  Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes.

Authors:  Mollie Jurewicz; Sunmi Yang; Andrea Augello; Jonathan G Godwin; Robert F Moore; Jamil Azzi; Paolo Fiorina; Mark Atkinson; Mohamed H Sayegh; Reza Abdi
Journal:  Diabetes       Date:  2010-09-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.